» Articles » PMID: 32025013

The Evolutionary History of 2,658 Cancers

Abstract

Cancer develops through a process of somatic evolution. Sequencing data from a single biopsy represent a snapshot of this process that can reveal the timing of specific genomic aberrations and the changing influence of mutational processes. Here, by whole-genome sequencing analysis of 2,658 cancers as part of the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA), we reconstruct the life history and evolution of mutational processes and driver mutation sequences of 38 types of cancer. Early oncogenesis is characterized by mutations in a constrained set of driver genes, and specific copy number gains, such as trisomy 7 in glioblastoma and isochromosome 17q in medulloblastoma. The mutational spectrum changes significantly throughout tumour evolution in 40% of samples. A nearly fourfold diversification of driver genes and increased genomic instability are features of later stages. Copy number alterations often occur in mitotic crises, and lead to simultaneous gains of chromosomal segments. Timing analyses suggest that driver mutations often precede diagnosis by many years, if not decades. Together, these results determine the evolutionary trajectories of cancer, and highlight opportunities for early cancer detection.

Citing Articles

Geographic and age-related variations in mutational processes in colorectal cancer.

Diaz-Gay M, Dos Santos W, Moody S, Kazachkova M, Abbasi A, Steele C medRxiv. 2025; .

PMID: 40034755 PMC: 11875255. DOI: 10.1101/2025.02.13.25322219.


Identification and multi-omics analysis of essential coding and long non-coding genes in colorectal cancer.

Li Y, Meng Z, Fan C, Rong H, Xi Y, Liao Q Biochem Biophys Rep. 2025; 41:101938.

PMID: 40034256 PMC: 11874739. DOI: 10.1016/j.bbrep.2025.101938.


Liquid biopsy in detecting early non-small cell lung cancer.

Rosell R, Santarpia M, Pedraz-Valdunciel C, Ciappina G, Aguilar A, Gimenez-Capitan A J Liq Biopsy. 2025; 1:100001.

PMID: 40027282 PMC: 11863710. DOI: 10.1016/j.jlb.2023.100001.


PIK3CA gene mutation status associated with poor prognosis of breast cancer: a retrospective cohort study.

Yan M, Zong Z, Guo W, Li X, Li J, Xia X BMC Cancer. 2025; 25(1):365.

PMID: 40016671 PMC: 11869396. DOI: 10.1186/s12885-025-13486-5.


Discovery of a selective PI3Kα inhibitor structure-based virtual screening for targeted colorectal cancer therapy.

Albassam H, Almutairi O, Alnasser M, Altowairqi F, Almutairi F, Alobid S J Enzyme Inhib Med Chem. 2025; 40(1):2468852.

PMID: 39992303 PMC: 11852364. DOI: 10.1080/14756366.2025.2468852.


References
1.
Brenner H, Hoffmeister M, Stegmaier C, Brenner G, Altenhofen L, Haug U . Risk of progression of advanced adenomas to colorectal cancer by age and sex: estimates based on 840,149 screening colonoscopies. Gut. 2007; 56(11):1585-9. PMC: 2095643. DOI: 10.1136/gut.2007.122739. View

2.
Welch J, Ley T, Link D, Miller C, Larson D, Koboldt D . The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012; 150(2):264-78. PMC: 3407563. DOI: 10.1016/j.cell.2012.06.023. View

3.
Gundem G, Van Loo P, Kremeyer B, Alexandrov L, Tubio J, Papaemmanuil E . The evolutionary history of lethal metastatic prostate cancer. Nature. 2015; 520(7547):353-357. PMC: 4413032. DOI: 10.1038/nature14347. View

4.
Alexandrov L, Jones P, Wedge D, Sale J, Campbell P, Nik-Zainal S . Clock-like mutational processes in human somatic cells. Nat Genet. 2015; 47(12):1402-7. PMC: 4783858. DOI: 10.1038/ng.3441. View

5.
Landau D, Tausch E, Taylor-Weiner A, Stewart C, Reiter J, Bahlo J . Mutations driving CLL and their evolution in progression and relapse. Nature. 2015; 526(7574):525-30. PMC: 4815041. DOI: 10.1038/nature15395. View